Inovio Inks $44M Cash, Stock Deal To End COVID-19 Vax Suit
Biotechnology firm Inovio Pharmaceuticals Inc. has reached a $44 million settlement agreement with its investors, which if approved would end claims that the company's misrepresentation of its COVID-19 vaccine development efforts...To view the full article, register now.
Already a subscriber? Click here to view full article